Lossen Rearrangement vs C–N Reductive Elimination Enabled by Rh(III)-Catalyzed C–H Activation/Selective Lactone Ring-Opening: Chemodivergent Synthesis of Quinolinones and Dihydroisoquinolinones
作者:Mengyao Bian、Hamdulla Mawjuda、Hui Gao、Huiying Xu、Zhi Zhou、Wei Yi
DOI:10.1021/acs.orglett.0c03734
日期:2020.12.18
An unprecedented Rh(III)-catalyzed cascade C–H activation/Lossen rearrangement of aromatic amides with methyleneoxetanones has been realized along with a tunable C–N bond reductive elimination/trans esterification, giving divergent access to quinolinones and dihydroisoquinolinones via selective ring-opening of the four-membered lactone unit. Combined computational and experimental mechanistic studies
Synergistic Dual Directing Groups-Enabled Diastereoselective C–H Cyclopropylation via Rh(III)-Catalyzed Couplings with Cyclopropenyl Alcohols
作者:Min Wu、Shuang Lin、Guoxun Zhu、Ming Sun、Zhi Zhou、Hui Gao、Wei Yi
DOI:10.1021/acs.orglett.9b04608
日期:2020.2.21
By using a synergisticdualdirecting group-assisted C-H activation strategy and simply modifying the reaction conditions, we realized a robust and general Cp*Rh(III)-catalyzedC-Hcyclopropylation of N-acetoxybenzamides with cyclopropenylalcohols, providing regio-, chemo-, and diastereoselective access to ortho trans- and cis-1,1-dimethylcyclopropane-functionalized benzamides in a redox-neutral and
3,7-DIAZYBICYCLO 3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS
申请人:AstraZeneca AB
公开号:EP1389211A1
公开(公告)日:2004-02-18
[EN] 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS<br/>[FR] PREPARATIONS 3,7-DIAZYBICYCLO [3.3.1] UTILISEES COMME COMPOSES ANTI-ARYTHMIQUES
申请人:ASTRAZENECA AB
公开号:WO2002083687A1
公开(公告)日:2002-10-24
There is provided a modified release pharmaceutical composition comprising 4-(3-[7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl]propyl}amino)benzonitrile, tert-butyl 2-7-[3-(4-cyano-anilino)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate, tert-butyl 2-7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate, or tert-butyl 2-7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate, or a pharmaceutically-acceptable salt of any of these compounds, in particular a gelling polymer matrix modified release composition. The compositions are useful in the prophylaxis and/or treatment of cardiac arrhythmias.